Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High at $17.09

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $17.09 and last traded at $16.85, with a volume of 1021114 shares traded. The stock had previously closed at $16.88.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TEVA shares. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the stock an "overweight" rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price objective on the stock in a research note on Friday, March 8th. StockNews.com cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Friday. Piper Sandler restated an "overweight" rating and set a $20.00 price target (up from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday. Finally, The Goldman Sachs Group lifted their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a "neutral" rating in a research note on Monday, February 5th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and an average price target of $14.22.

Teva Pharmaceutical Industries Stock Up 1.2 %

The company has a market cap of $19.16 billion, a PE ratio of -41.59, a PEG ratio of 1.95 and a beta of 1.04. The stock's 50 day moving average price is $13.88 and its 200-day moving average price is $11.92. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.61 and a current ratio of 0.89.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the sale, the executive vice president now directly owns 382,590 shares of the company's stock, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Eric Drape sold 173,261 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the transaction, the vice president now owns 1 shares in the company, valued at approximately $13.05. The disclosure for this sale can be found here. Insiders have sold 358,972 shares of company stock valued at $4,739,820 over the last ninety days. 0.55% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. EntryPoint Capital LLC purchased a new position in Teva Pharmaceutical Industries during the 1st quarter worth $30,000. Blue Trust Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 92.3% during the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock worth $46,000 after purchasing an additional 2,180 shares during the last quarter. Signaturefd LLC lifted its position in Teva Pharmaceutical Industries by 90.8% during the third quarter. Signaturefd LLC now owns 5,032 shares of the company's stock valued at $51,000 after purchasing an additional 2,394 shares during the period. Psagot Value Holdings Ltd. Israel purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $57,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $82,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.